Follow us on Twitter

Saturday 7 November 2015

RSV MUCOSAL VACCINE - KIDO HIROSHI

http://www.freepatentsonline.com/y2015/0297713.html

Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations | European Respiratory Society

http://erj.ersjournals.com/content/46/suppl_59/PA3625

WHO | Influenza update

This update is fascinating. As the flu season in the northern hemisphere approaches its interesting to note that in Australia the dominant viruses have been of the B subtype. Currently most vaccines in the northern hemisphere only protect against one B virus, although a new vaccine which protects against two is available and the Australian government is now switching to this. It seem highly likely that Northern Hemisphere governments will have to follow suit.



http://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/

VBI Vaccines to Present Update and New Data Supporting its RSV and CMV Vaccine Programs at the World Vaccine Congress Europe - NASDAQ.com

http://www.nasdaq.com/press-release/vbi-vaccines-to-present-update-and-new-data-supporting-its-rsv-and-cmv-vaccine-programs-at-the-20151106-00374

Monday 2 November 2015

Reference "Influence of Statins on Influenza Vaccine Response..."

J. Infect. Dis., 2015

Influence of Statins on Influenza Vaccine Response in Elderly Individuals.

Black, S; Nicolay, U; Del Giudice, G; Rappuoli, R

Influenza vaccination strategies have targeted elderly individuals because they are at high risk of disease complications and mortality. Statins are a class of drugs used to treat hypercholesterolemia and are frequently used in the elderly population to reduce the risk of cardiovascular disease. However, statins are also known to have immunomodulatory effects that could impact influenza vaccine response. In a post hoc analysis, we performed a cross-sectional observational study nested within a comparative immunogenicity clinical trial of adjuvanted versus unadjuvanted influenza vaccine in elderly persons to evaluate the influence of statin therapy on the immune response to vaccination. Overall, data on >5000 trial participants were available for analysis. Comparison of hemagglutination-inhibiting geometric mean titers to influenza A(H1N1), A(H3N2), and B strains revealed that titers were 38% (95% confidence interval [CI], 27%-50%), 67% (95% CI, 54%-80%), and 38% (95% CI, 28%-29%) lower, respectively, in subjects receiving chronic statin therapy, compared with those not receiving chronic statin therapy. This apparent immunosuppressive effect of statins on the vaccine immune response was most dramatic in individuals receiving synthetic statins. These effects were seen in both the adjuvanted and unadjuvanted vaccine groups in the clinical trial. These results, if confirmed, could have implications both for future clinical trials design, as well as for vaccine use recommendations for elderly individuals.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMID: 26516142
URL - http://www.ncbi.nlm.nih.gov/pubmed/26516142?dopt=Citation

Posted by Rob Lambkin-Williams

Reference "Influence of Statins on Influenza Vaccine Response..."

J. Infect. Dis., 2015

Influence of Statins on Influenza Vaccine Response in Elderly Individuals.

Black, S; Nicolay, U; Del Giudice, G; Rappuoli, R

Influenza vaccination strategies have targeted elderly individuals because they are at high risk of disease complications and mortality. Statins are a class of drugs used to treat hypercholesterolemia and are frequently used in the elderly population to reduce the risk of cardiovascular disease. However, statins are also known to have immunomodulatory effects that could impact influenza vaccine response. In a post hoc analysis, we performed a cross-sectional observational study nested within a comparative immunogenicity clinical trial of adjuvanted versus unadjuvanted influenza vaccine in elderly persons to evaluate the influence of statin therapy on the immune response to vaccination. Overall, data on >5000 trial participants were available for analysis. Comparison of hemagglutination-inhibiting geometric mean titers to influenza A(H1N1), A(H3N2), and B strains revealed that titers were 38% (95% confidence interval [CI], 27%-50%), 67% (95% CI, 54%-80%), and 38% (95% CI, 28%-29%) lower, respectively, in subjects receiving chronic statin therapy, compared with those not receiving chronic statin therapy. This apparent immunosuppressive effect of statins on the vaccine immune response was most dramatic in individuals receiving synthetic statins. These effects were seen in both the adjuvanted and unadjuvanted vaccine groups in the clinical trial. These results, if confirmed, could have implications both for future clinical trials design, as well as for vaccine use recommendations for elderly individuals.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMID: 26516142
URL - http://www.ncbi.nlm.nih.gov/pubmed/26516142?dopt=Citation


cheers Rob

Sent from a device with a ridiculously small keyboard , apologies for any tyops.

Influenza Vaccine Less Effective in Seniors Taking Statins | Guardian Liberty Voice

http://guardianlv.com/2015/10/influenza-vaccine-less-effective-in-seniors-taking-statins/

Posted by Rob Lambkin-Williams